Remedy Pharmaceuticals to Showcase Groundbreaking Phase 3 CHARM Study Data on CIRARA® at International Stroke Conference 2025
Remedy Pharmaceuticals, the developer of CIRARA (intravenous glyburide) for the treatment of Large Hemispheric Infarction (LHI) today announced three speaker presentations of efficacy data from both the Phase 2 GAMES-RP and Phase 3 CHARM study on its stroke drug, CIRARA, will be presented at the upcoming International Stroke Conference (ISC) being held February 5-7, 2025 […]